Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Market Expected To Reach $4.44 Billion By 2030 At 21.3% CAGR
The market for AI-powered remote intravenous patient monitoring has experienced remarkable expansion lately. This sector is projected to increase from $1.69 billion in 2025 to $2.05 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 21.6%. Factors contributing to this growth during the preceding period include the escalating application of IV therapies in healthcare settings, a rise in complications associated with infusions, the broader implementation of patient monitoring systems within hospitals, enhanced integration of smart infusion devices, and a heightened emphasis on protocols aimed at ensuring medication safety.
The market for artificial intelligence-powered remote patient intravenous drip monitoring is poised for substantial expansion, projecting a valuation of $4.45 billion by 2030, driven by an anticipated compound annual growth rate of 21.3%. This upward trajectory in the projected period is fueled by several key factors: a greater acceptance of AI-driven infusion oversight, a heightened need for IV therapy administered at home, broader implementation of analytics for predicting patient safety, increased incorporation of networked infusion devices, and a stronger focus on monitoring patients remotely. Key developments shaping this market in the coming forecast period involve a rise in the adoption of real-time analysis of IV fluid flow, increased utilization of AI for identifying infusion mistakes, greater integration of intelligent sensors for infusions, an expansion in the management of at-home IV therapies, and an amplified dedication to patient safety and adherence to protocols.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28921&type=smp
Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Market Growth Drivers: What Factors Are Accelerating Expansion?
The burgeoning expansion of telehealth services is poised to accelerate the market expansion for artificial intelligence (AI) driven remote patient intravenous (IV) monitoring. Telehealth encompasses the provision of healthcare remotely via digital communication technologies, facilitating consultations, health oversight, and treatment without physical proximity. Regulatory adjustments and reimbursement policy shifts implemented during the COVID-19 pandemic significantly boosted telehealth’s accessibility and financial feasibility for both patients and healthcare providers. AI-enhanced remote patient IV monitoring complements telehealth by offering continuous, real-time oversight of patients’ IV therapies, automatically identifying potential complications, furnishing vital insights to medical professionals, and integrating seamlessly with virtual care systems. This integration aims to ensure prompt medical interventions, enhance patient safety, and optimize the management of treatments administered at home or on an outpatient basis. Illustratively, FAIR Health Inc. reported in April 2023 that national telehealth utilization saw a 7.3% increase in 2023, climbing from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Consequently, the expansion of telehealth services serves as a key catalyst for the growth of the AI-enhanced remote patient intravenous (IV) monitoring market.
The widespread adoption of wearable health technologies is projected to be a significant driver for the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market. These wearable devices, including smartwatches and fitness trackers, are capable of real-time monitoring of various physiological indicators. A heightened awareness of personal health and a desire for tools that offer immediate insights into well-being are fueling the increased use of these technological aids, prompting individuals to actively track their health metrics and vital signs. By continuously gathering real-time physiological data from patients, wearable health technologies facilitate remote patient IV monitoring. This data can subsequently be analyzed to detect deviations from normal patterns, refine IV treatment protocols, and enable personalized interventions without the necessity for constant direct medical supervision. As an example, the UK Parliament’s House of Commons Library noted that between 2023 and 2024, approximately USD 15 million (£11.5 million) was invested by the NIHR and UKRI into ten distinct research initiatives dedicated to the development of wearable technologies aimed at fostering greater independence for individuals experiencing frailty or long-term physical disabilities. Therefore, the increasing prevalence of wearable health technologies is significantly contributing to the expansion of the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market.
Escalating healthcare expenditure is anticipated to stimulate the growth trajectory of the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market. This rise in healthcare spending refers to the aggregate financial investment in healthcare goods and services over a defined timeframe. An increasing demand for sophisticated medical technologies and services, aimed at improving patient outcomes, boosting treatment efficacy, and supporting the integration of AI-powered remote patient monitoring systems, is driving this upward trend in expenditure. Heightened healthcare spending provides the necessary financial backing for advanced technologies, digital infrastructures, and personnel training essential for implementing and operating AI-enhanced remote patient IV monitoring systems, thereby ensuring more effective and precise patient care. For instance, according to the Centers for Medicare & Medicaid Services, national health expenditures in the US reached $4.9 trillion in 2023, marking a 7.5% increase and averaging $14,570 per capita, representing 17.6% of the Gross Domestic Product. Medicare spending alone rose by 8.1% to $1,029.8 billion, constituting 21% of the total national health expenditures. Consequently, the increase in healthcare expenditure is a primary driver for the growth of the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market.
Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Market Segment Analysis Highlighting Growth Areas
The artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market covered in this report is segmented –
1) By Component: Hardware, Software, Services
2) By Deployment Mode: On-Premises, Cloud-Based
3) By Application: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers, Other Applications
4) By End-User: Healthcare Providers, Patients
Subsegments:
1) By Hardware: Patient Monitoring Devices, Sensors And Infusion Pumps, Communication Devices, Data Storage Systems
2) By Software: Predictive Analytics Software, Clinical Decision Support Software, Remote Monitoring Software, Data Management Software
3) By Services: Implementation And Integration Services, Maintenance And Support Services, Training And Education Services, Remote Monitoring Services
Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market are Medtronic plc, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, Epic Systems Corporation, ICU Medical Inc., InfuSystem Holdings Inc., AlayaCare Inc., Huma Therapeutics Ltd., Health Recovery Solutions Inc., Arcomed AG, VitalConnect Inc., Cloud DX Inc., Empatica S.r.l., AccuHealth Inc., Serum Tracker Inc.
Access The Complete Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Market Report:
Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
